Background: Rheumatic musculoskeletal disorders (RMSDs) are a common cause of long term pain and physical disability. In developed countries, RMSDs are a major cause of absence from work and thus have a big financial burden on the country economic status. Several studies have been published the incidence and prevalence of RMSDs in different world countries and found to be widely variable. Estimation of the extend of the problem of RMSDs in developing world, especially in rural economies will help better understanding of the risk factors that contribute to the initiation and progression of these diseases and help the health care authorities to provide proper health program services in these areas to reduce the physical and financial burden of RMSDs (Bagher et al., 2011; Majumdar et al., 2015 and Usenbo, et al., 2015).

Objectives: To estimate the prevalence rate of RMSDs in a rural population in Upper Egypt.

Methods: A cross-sectional based study was carried out and included 3988 subjects of population (2013 females and 1975 males). Mean age of patients was (46.89±15.25yrs). They proceeded 4 phases of World Health Organization/International League of Associations for Rheumatology community-oriented program for control of rheumatic diseases survey questionnaire WHO-ILAR Community Oriented Program for screening of rheumatic diseases. Modified Health Assessment Questionnaire (HAQ) was used to assess the disability severity. Individuals suspected to have any rheumatic diseases were subjected to full clinical examination, laboratory and radiological investigations to reach a final diagnosis. They were classified according to appropriate criteria of diagnosis of diseases.

Results: A prevalence rate of RMSDs was 16.22%, more prevalence in females (10.38% vs. 5.84% for males, P=0.000). The mean age of patients with RRMSDs were older (46.89±15.25 yrs) than healthy individuals (29.56±18.95 yrs) (P=0.0001) and with increasing age (≥45≤ 55 yrs). The identified RMSDs were OA (8.5%), Soft tissue rheumatism (STR) (6.57%), spinal disorders (SD) (6.47%), fibromyalgia (FM) (0.60%), RA (0.30%), arthralgia (0.18%), SPAs (0.15%), Gout(0.6%), Pseudogout (0.08%), SLE (0.5%), JIA(0.03) and MCTD (0.03%). The prevalence rates for the majority of RRMSDs were higher in females and with increasing age. About two thirds of the patients had grade II disability.

Conclusion: The prevalence rate of RMSDs in a rural population ≥15years in Upper Egypt has been estimated to be 16.22%. The most prevalent RMSDs are OA, STR and SD causing the greatest burden of the disease. The predictive risk of RMSDs has to be assessed in future studies.

References:

- [1] Majumdar A, Kumar SG, Nair D, Sujiv A. Musculoskeletal complaints and predictors of musculoskeletal pain among adults in rural puducherry. Indian J Palliat Care. 2015; 21(1):121-123.
- [2] Usenbo A, Kramer V, Young T, Musekiwa A. Prevalence of Arthritis in Africa: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10 (8):e0133858.
- [3] Bagher OM, Golbarg M, Hossein S. Pattern of rheumatic diseases in two outpatient clinics in Iran: similarities with some different features. Indian J Med Sci. 2011; 65(1):7-17.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.779

AB1228 COMPARATIVE ANALYSIS OF COMORBID PATHOLOGY IN PATIENTS WITH RHEUMATOID ARTHRITIS AND ANKYLOSING SPONDYLITIS

T. Raskina¹, O. Malyshenko¹, E. Usova¹, M. Letaeva¹, J. Averkieva¹. ¹Federal State Educational Institution of Higher Education "Kemerovo State Medical University", Kemerovo, Russian Federation

Background: Interest in comorbid conditions in rheumatoid arthritis (RA) and ankylosing spondylitis (AS) is due to their influence on the course and prognosis of the disease itself, the quality of life of patients and the choice of treatment tactics.

Objectives: To compare the frequency and structure of comorbid pathology in patients with RA and AS.

Methods: 130 cases of patients with RA (95 women, 35 men, average age 47±6.6 years) and 86 with AS (27 women and 59 men, average age 44 ±7.4 years) were analyzed. The effect of concomitant pathology on the long-term prognosis was evaluated using the Charlson comorbidity index.

Results: Patients with RA had a combined pathology in 93.0% (122) cases, of which 24.5% (30) – one, 28.6% (35) – two, 46.7% (57) – three or more concomitant diseases. Concomitant diseases in AS patients were registered in 83.7% (72) of cases, including one in 36% (31), two in 14% (12), and three or more in 33.7% (29). The Charlson index from 1 to 2 points was determined in 78.5% (102) of RA patients and in 77.9% (69) of patients with AS (p=0.067). Values from 3 to 4 points had 19.2% (25) and 20.9% (18) of patients, respectively (p=0.064). The Charlson index of more than 5 points was registered in 2.3% (3) patients with RA and 1.2% (1) patients with AS.

The leading place in the structure of comorbidity in the group of patients with RA was occupied by diseases of the digestive system, which was observed in 79.2% (103) of patients. In the second place in the same group were registered cardiovascular diseases (CVD) – in 48.5% (63) patients, the most common arterial hypertension

– in 36.9% (48). 27.6% (36) of patients had chronic pyelonephritis in combination with urolithiasis. Osteoporosis was detected in 20.0% (26) of RA patients.

In the group of patients with AS, diseases of the digestive system were also most frequently registered – in 76.7% (66) of patients. CVD was observed in 41.9 % (36) patients, of which 39.5% (34) had hypertension. Kidney diseases were registered in 9.3% (8) of patients. Osteoporosis was detected in 32.5% (28) of patients with AS.

Comparative analysis of the structure and frequency of diseases of the digestive system in RA and AS revealed no significant differences. CVD was registered more often in RA than in AS (48.5% vs 41.8%, p=0.037). There were significant differences in the frequency of hypertension in the study groups of patients: hypertension was observed more often in patients with AS in 39.5% of cases, while in RA only in 36.9% (p=0.041), which is probably due to long-term use of medium and high doses of NSAIDs as "basic therapy" for AS. Kidney diseases were more common in RA than in AS (27% vs 9.3%, p=0.022). Osteoporosis, in contrast, was most frequently detected in patients with AS than in RA patients (32.2% vs 20%, p=0.047).

Conclusion: Despite differences in the pathogenesis of RA and AS, the long-term prognosis, determined by both rheumatic disease and comorbidities, did not differ significantly. Concomitant pathology is an important component that determines the management of patients.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2020-eular.5650

AB1229 SAFETY OF BIOSIMILAR ETANERCEPT IN THE TREATMENT OF RHEUMATIC DISEASES: DATA FROM THE MEXICAN ADVERSE EVENTS REGISTRY (BIOBADAMEX)

V. Rivera Teran¹, M. Pérez Rodríguez², D. Alpizar-Rodríguez³, F. Irazoque-Palazuelos⁴, S. Carrillo⁴, S. Sicsik⁴, D. Vega-Morales⁴, D. Miranda⁴, A. Castillo⁴, J. C. Casasola⁴, C. F. Pacheco Tena⁴, J. F. Moctezuma⁴, F. Aceves⁴, A. Paz⁴, S. Duran Barragan⁴, L. Barile⁴, N. Santana⁴, D. X. Xibille Friedmann⁴.

¹Colegio Mexicano de Reumatología, Unidad de Investigación, Mexico City, Mexico;

²Instituto Mexicano del Seguro Social, Centro de Adiestramiento

en Investigación Clínica, Mexico City, Mexico;

³Colegio Mexicano de Reumatología, Unidad de Investigación, Mexico City, Mexico;

⁴Colegio Mexicano de Reumatología, Mexico City, Mexico

Background: Access to biosimilar drugs in Mexico started on 2014. Although biosimilar drugs safety has proved comparability to originator drugs on trials, information about its safety on real-life data is limited.

Objectives: To compare safety in terms of adverse events of biosimilar etanercept (BEt) to originator etanercept (OEt) using information from the Mexican Adverse Events Registry (BIOBADAMEX).

Methods: BIOBADAMEX is a Mexican cohort that collects the information of biologic and biosimilar drugs used in patients with rheumatic diseases in public and private practice since 2016. Patients enrolled are followed- up yearly. For this study we included patients from 18 to 65 years old who were or are currently in treatment with OEt or BEt and analyzed the frequency of adverse events (AE), the severity and the outcome of these. Baseline time was considered at enrolment to the cohort. We used logistic regression to analyze univariable and multivariable associations.

Results: At the time of analysis a total of 119 have received treatment with OEt, 38 with BEt. Mean follow up time was 1.35 years. Rheumatoid arthritis (RA) was the most common disease for all the groups followed by ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Both groups had similar baseline characteristics (Table 1). AE occurred in 4 (3.4%) patients with OEt and in 6 (15.8%) with BEt (OR 0.2, 95% CI 0.04-0.7). The most frequent AE in OEt group was allergic reaction, (2(2.5%) of patients), and infections were the most frequent AE in BEt group (2 (5.3%)). Of patients with BEt, 2(5.3%) had severe AE compared to none in the OEt (p=0.012). In the multivariable adjusted analysis comparing development of AE vs no AE including BEt, comorbidities and glucocorticoids, we found that use of BEt (OR 4.6, 95%CI 1.1-19.5) and presence of comorbidities (OR 4.6, 95%CI 1.01-20.5), were associated with AE. Use of glucocorticoids was not significantly associated.

Table 1. Baseline characteristics

	Originator etanercept (n=119)	Biosimilar Etanercept (n=38)	Univariable Analysis ^a OR(95%CI)
Sex (female), n(%)	98 (82.4)	27 (71.0)	1.9 (0.8-4.4)
Age, median (IQR)	53.6 (45-61)	51.3 (43-58)	1.0 (0.9-1.0)
Body Mass Index, median (IQR)	27.5 (23.4-32.5)	26.7 (24-29)	1.0 (0.9-1.1)
Diagnosis, n(%)			
Rheumatoid arthritis	98 (82.4)	26 (68)	1
Ankylosing spondylitis	13 (10.9)	9 (24.0)	0.3 (0.1-0.9)
Psoriatic arthritis	8 (6.9)	3 (8.0)	0.7 (0.1-2.8)
Comorbidities, n(%)	41 (34.5)	14 (40.0)	0.3 (0.3-1.5)